CO4940489A1 - NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALS - Google Patents
NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALSInfo
- Publication number
- CO4940489A1 CO4940489A1 CO98040749A CO98040749A CO4940489A1 CO 4940489 A1 CO4940489 A1 CO 4940489A1 CO 98040749 A CO98040749 A CO 98040749A CO 98040749 A CO98040749 A CO 98040749A CO 4940489 A1 CO4940489 A1 CO 4940489A1
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- thiazolidin
- dione
- benzyl
- cinema
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Un producto para el tratamiento de la diabetes mellitus y lascondiciones asociadas con la diabetes mellitus en un mamífero, cuyo producto comprende administrar una cantidad ====== no tóxica y farmacéuticamente aceptable de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucémico inhibidor de alfa-glocosidasa, a un mamífero que necesita del mismo.1Un producto de acuerdo con la reinvindicación 1, en el que el sensibilizador a insulina es (+)-5-[[4-[(3,4-dihidro-6-hidroxi-2,5,7,8-tetrametil-2H-1-benzopiran-2-il)metoxi]fenil]metil]-2,4- tiazolidindiona (o troglitazona), 5-[4-[(1-metil-ciclohexil)metoxi]bencil]tiazolidin-2,4-diona (o ciglitazona), 5-[4-[2-(5-etil-piridin-2-il)etoxi]bencil]-tiazolidin-2,4-diona (o pioglitazona) o 5-[(2-bencil-2,3-dihidro-benzopiran) -5-ilmetil] tiazolidin-2,4-diona (o englitazona); o una forma farmacéuticamente aceptable del mismo.A product for the treatment of diabetes mellitus and the conditions associated with diabetes mellitus in a mammal, the product of which comprises administering a ====== non-toxic and pharmaceutically acceptable amount of an insulin sensitizer, an insulin secretagogue and an agent. alpha-glocosidase inhibitor antihyperglycemic, to a mammal in need thereof.1 A product according to claim 1, wherein the insulin sensitizer is (+) - 5 - [[4 - [(3,4-dihydro- 6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl) methoxy] phenyl] methyl] -2,4-thiazolidinedione (or troglitazone), 5- [4 - [(1- methyl-cyclohexyl) methoxy] benzyl] thiazolidin-2,4-dione (or ciglitazone), 5- [4- [2- (5-ethyl-pyridin-2-yl) ethoxy] benzyl] -thiazolidin-2,4- dione (or pioglitazone) or 5 - [(2-benzyl-2,3-dihydro-benzopyran) -5-ylmethyl] thiazolidin-2,4-dione (or englitazone); or a pharmaceutically acceptable form thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9715298A GB9715298D0 (en) | 1997-07-18 | 1997-07-18 | Novel method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4940489A1 true CO4940489A1 (en) | 2000-07-24 |
Family
ID=10816170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98040749A CO4940489A1 (en) | 1997-07-18 | 1998-07-17 | NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALS |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1001784A1 (en) |
| JP (1) | JP2001510160A (en) |
| KR (1) | KR20010021952A (en) |
| CN (1) | CN1263467A (en) |
| AP (1) | AP2000001735A0 (en) |
| AR (2) | AR016350A1 (en) |
| AU (1) | AU8449098A (en) |
| BG (1) | BG104062A (en) |
| BR (1) | BR9810292A (en) |
| CA (1) | CA2297133A1 (en) |
| CO (1) | CO4940489A1 (en) |
| DZ (1) | DZ2563A1 (en) |
| EA (1) | EA200000140A1 (en) |
| GB (1) | GB9715298D0 (en) |
| HU (1) | HUP0003626A3 (en) |
| ID (1) | ID23804A (en) |
| IL (1) | IL133907A0 (en) |
| MA (1) | MA24608A1 (en) |
| NO (1) | NO20000230L (en) |
| OA (1) | OA11312A (en) |
| PE (1) | PE99499A1 (en) |
| PL (1) | PL338140A1 (en) |
| SK (1) | SK612000A3 (en) |
| TR (1) | TR200000133T2 (en) |
| UY (1) | UY25101A1 (en) |
| WO (1) | WO1999003478A1 (en) |
| ZA (1) | ZA986364B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| DK1133312T3 (en) | 1999-06-21 | 2008-01-02 | Lilly Co Eli | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof for the treatment of non-insulin-dependent diabetes |
| ES2301142T3 (en) * | 2000-01-21 | 2008-06-16 | Novartis Ag | COMBINATIONS THAT INCLUDE INHIBITORS OF DIPEPTIDILPEPTIDASA-IV AND ANTIDIABETIC AGENTS. |
| EP1295609A4 (en) * | 2000-02-24 | 2004-11-03 | Takeda Chemical Industries Ltd | Drugs containing combined active ingredients |
| JP4917712B2 (en) * | 2000-02-24 | 2012-04-18 | 武田薬品工業株式会社 | Concomitant medication |
| US7964216B2 (en) | 2001-01-12 | 2011-06-21 | Sun Pharma Advanced Research Company Limited | Spaced drug delivery system |
| FR2832930A1 (en) * | 2001-12-03 | 2003-06-06 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-GLUCOSIDASE INHIBITOR AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES |
| CN1874774B (en) | 2003-10-31 | 2011-04-13 | 武田药品工业株式会社 | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
| CN101103993B (en) * | 2006-07-14 | 2011-03-30 | 北京华安佛医药研究中心有限公司 | Hypoglycemic medicine composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0601001T3 (en) * | 1991-08-26 | 1997-10-20 | Upjohn Co | Liquid food product containing 3-guanidinopropionic acid. |
| US5917052A (en) * | 1994-09-28 | 1999-06-29 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
-
1997
- 1997-07-18 GB GB9715298A patent/GB9715298D0/en active Pending
-
1998
- 1998-07-15 DZ DZ980173A patent/DZ2563A1/en active
- 1998-07-16 IL IL13390798A patent/IL133907A0/en unknown
- 1998-07-16 BR BR9810292-3A patent/BR9810292A/en not_active IP Right Cessation
- 1998-07-16 AU AU84490/98A patent/AU8449098A/en not_active Abandoned
- 1998-07-16 EA EA200000140A patent/EA200000140A1/en unknown
- 1998-07-16 JP JP2000502777A patent/JP2001510160A/en active Pending
- 1998-07-16 ID IDW20000077A patent/ID23804A/en unknown
- 1998-07-16 HU HU0003626A patent/HUP0003626A3/en unknown
- 1998-07-16 PE PE1998000630A patent/PE99499A1/en not_active Application Discontinuation
- 1998-07-16 CA CA002297133A patent/CA2297133A1/en not_active Abandoned
- 1998-07-16 PL PL98338140A patent/PL338140A1/en unknown
- 1998-07-16 WO PCT/GB1998/002112 patent/WO1999003478A1/en not_active Application Discontinuation
- 1998-07-16 KR KR1020007000517A patent/KR20010021952A/en not_active Application Discontinuation
- 1998-07-16 MA MA25172A patent/MA24608A1/en unknown
- 1998-07-16 SK SK61-2000A patent/SK612000A3/en unknown
- 1998-07-16 EP EP98935129A patent/EP1001784A1/en not_active Withdrawn
- 1998-07-16 AR ARP980103482A patent/AR016350A1/en unknown
- 1998-07-16 CN CN98807147A patent/CN1263467A/en active Pending
- 1998-07-16 TR TR2000/00133T patent/TR200000133T2/en unknown
- 1998-07-17 UY UY25101A patent/UY25101A1/en not_active Application Discontinuation
- 1998-07-17 CO CO98040749A patent/CO4940489A1/en unknown
- 1998-07-17 ZA ZA9806364A patent/ZA986364B/en unknown
-
1999
- 1999-06-28 AR ARP990103110A patent/AR019724A2/en unknown
-
2000
- 2000-01-06 BG BG104062A patent/BG104062A/en unknown
- 2000-01-14 AP APAP/P/2000/001735A patent/AP2000001735A0/en unknown
- 2000-01-17 NO NO20000230A patent/NO20000230L/en not_active Application Discontinuation
- 2000-01-18 OA OA1200000013A patent/OA11312A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA11312A (en) | 2003-10-24 |
| MA24608A1 (en) | 1999-04-01 |
| SK612000A3 (en) | 2000-07-11 |
| HUP0003626A2 (en) | 2001-05-28 |
| ZA986364B (en) | 2000-01-17 |
| AP2000001735A0 (en) | 2000-01-16 |
| AR016350A1 (en) | 2001-07-04 |
| CA2297133A1 (en) | 1999-01-28 |
| PL338140A1 (en) | 2000-09-25 |
| CN1263467A (en) | 2000-08-16 |
| GB9715298D0 (en) | 1997-09-24 |
| IL133907A0 (en) | 2001-04-30 |
| KR20010021952A (en) | 2001-03-15 |
| DZ2563A1 (en) | 2003-02-15 |
| WO1999003478A1 (en) | 1999-01-28 |
| NO20000230D0 (en) | 2000-01-17 |
| EP1001784A1 (en) | 2000-05-24 |
| PE99499A1 (en) | 1999-12-18 |
| BG104062A (en) | 2000-11-30 |
| TR200000133T2 (en) | 2000-09-21 |
| HUP0003626A3 (en) | 2001-12-28 |
| JP2001510160A (en) | 2001-07-31 |
| EA200000140A1 (en) | 2000-06-26 |
| BR9810292A (en) | 2000-09-19 |
| AU8449098A (en) | 1999-02-10 |
| UY25101A1 (en) | 2000-12-29 |
| AR019724A2 (en) | 2002-03-13 |
| ID23804A (en) | 2000-05-11 |
| NO20000230L (en) | 2000-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5300392A1 (en) | NEW COMPOSITION AND USE | |
| MY129897A (en) | Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus | |
| CO4940420A1 (en) | NEW METHOD OF TREATMENT | |
| CO4940489A1 (en) | NEW METHOD OF TREATMENT CINEMA ASSOCIATED WITH THE SAME IN MAMMALS | |
| EP1593379A3 (en) | Uses of PPAR-gamma agonists in neutrophil-induced diseases | |
| NO314065B1 (en) | Pharmaceutical composition comprising an insulin sensitivity enhancer and etbiguanide in the treatment of diabetes | |
| NO2963A (en) | Use of the compound 5- [4- [2- (5-ethylpyridin-2-yl) -ethoxy] benzyl] thiazolidine-2,4-dione (pioglitazone) for the manufacture of a medicament for the treatment of impaired glucose tolerance | |
| CO4940422A1 (en) | NOVEL TREATMENT METHOD | |
| WO2000076488A3 (en) | Use of a ppar agonist for treating type 1 diabetes | |
| US5708012A (en) | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus | |
| PE20001428A1 (en) | MODIFIED RELEASE COMPOSITION | |
| AR015894A1 (en) | USE OF 5- [4- [2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI] BENCIL] TIAZOLIDIN-2,4-DIONA AND INSULIN FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINS SUCH COMPOUNDS | |
| NZ513922A (en) | Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione | |
| AP1600A (en) | Combination of a thiazolidinedione and a sulphonylurea for treating diabetes | |
| PE20001239A1 (en) | COMPOSITION OF AN INSULIN SENSITIZER | |
| NZ522730A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| UY25051A1 (en) | COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS | |
| BR0111536A (en) | Thiazolidinedione salt for diabetes mellitus treatment | |
| BR0112982A (en) | Thiazolidinedione derivative tartrate salt | |
| DK1315724T3 (en) | Thiazolidinedione derivative and its use as an anti-diabetic | |
| NO20075507L (en) | Thiazolidinedione derivatives and their use as antidiabetic agents | |
| MXPA02012619A (en) | Treatment and prevention of cardiac insulin resistance associated conditions. | |
| HUP0003673A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AU2000254153A1 (en) | Treatment and prevention of cardiac insulin resistance associated conditions | |
| HRP20000255A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia |